Tablets-au.com Available ED Drugstore is an 1st. pharmacy providing a individual service to the society in Australia. Over 80,000 extremely satisfied buyers! We're your medication drug store cialis australia and have provided trusted service to families in Australia for over 15 years.

Herford.work.conquest-cms.net

Originalien im "peer-review" Verfahren
Malessa R, Agelink MW, Diener
HC. Dysfunction of visual
pathways in HIV-1 Infection. J
Neurol Sci 1995, 130: 82-87.
Malessa R, Agelink MW, van
Schayck R, Mertins L, Brockmeyer
NH. Elektrodermale Reflexaktivität
und 30:15 Ratio bei HIV-1
Infektion. Akt Neurol 1995, 22:
131-135.
Dammers S, Zeit T, Leonhardt M,
Schär V, Agelink MW. Malignes
neuroleptisches Syndrom. Dtsch
med Wschr 1995, 120: 1739-1742.
Malessa R, Agelink MW,
Himmelmann M, Kloss T, Mertins
L, Brockmeyer NH. Nerve
conduction changes in
asymptomatic HIV-1 seropositive
individuals in the ab-sence of other
risk factors for neuropathy.
Electromyogr Clin Neurophysiol
1996, 36: 3-8.
Agelink MW, Dammers S, Zeit T.
Clonidin- Abususrisiko beipsychisch kranken Patienten?Nervenarzt 1996, 67: 253-255.
Malessa R, Ohrmann P, Agelink
MW
, Brockmeyer NH, Diener HC.
HIV-1-assoziierte autonome
Dysfunktion (HIVAD). Nervenarzt
1996, 67: 147-154.
Malessa R, Agelink MW, Hengge
U, Mertins L, Gastpar M,
Brockmeyer NH. Oligosymptomatic
neurosyphilis with false negative
CSF-VDRL in HIV-infected
individuals? Eur J Med Res 1996,
1: 299-302.
Agelink MW, Zitzelsberger A,
Klieser E. Withdrawal syndrome
after discontinuation of
venlafaxine. Am J Psychiatry 1997,
154: 1473-1474.
Agelink MW, Dammers S,
Malessa R, Leonhardt M,
Zitzelsberger A, Ullrich H,
T. Nutzen und Risiken derElektrokrampfbehandlung beiälteren Patienten mitkardiovaskulären Risikofaktoren.
Nervenarzt 1998, 69: 70-75.
Agelink MW, Dirkes-Kersting A,
Zeit T, Bertling R, Malessa R,
Klieser E. Sensitivity of
carbohydrate deficient transferrin
(CDT) in relation to age and
duration of abstinence. Alcohol &
Alcoholism 1998, 33: 164-167.
Agelink MW, Malessa R, Kamcili
E, Zeit T, Lemmer W, Bertling R,
Klieser E. Cardiovascular
autonomic reactivity in
schizophrenics under neuroleptic
treatment: A potential predictor of
short term outcome?
Neuropsychobiology 1998, 38:
19-24.
Agelink MW, Malessa R, Weisser
U, Lemmer W, Zeit T, Majewski T,
Klieser E. Alcoholism, peripheral
neuropathy (PNP) and
cardiovascular autonomic
neuropathy (CAN). J Neurol Sci
1998, 161: 135-142.
Agelink MW, Malessa R, Lemmer
W, Zeit T, Majewski T, Klieser E.
Improved autonomic neurocardial
balance in short term abstinent
alcoholics treated with
acam-prosate. Alcohol &
Alcoholism 1998, 33: 602-605.
Agelink MW, Zeit T, Klieser E.
Prolonged bradycardia
complicated combined venlafaxineand electroconvulsive therapy. Br JPsychiatry 1998, 173: 441.
Agelink MW, Ullrich H, Lemmer
W, Dirkes-Kersting A, Zeit T.
Screening for concomitant alcohol
abuse in schizophrenia: Clinical
significance of the Munich
Alco-holism Test and laboratory
parameters. Eur Addict Res 1999,
5: 82-87.
Wurthmann C, Gregor J, Agelink
MW
, Effenberger O, Baumann B,
Döhring W, Bogerts B.
Morphometrische Untersuchung
der Hirnmorphologie bei
Agoraphobien. Psycho 2000, 26:
451-454.
Postert T, Lack B, Kuhn W, Jergas
M, Andrich J, Braun B, Przuntek
H, Sprengelmeyer R, Agelink
MW
, Büttner T. Basal ganglia
alterations and brain atrophy in
Huntington`s disease depicted by
transcranial real time sonography.
J Neurol Neurosurg Psychiatry
1999, 67: 457-462.
Agelink MW, Majewski T,
Wurthmann C, Lukas K, Ullrich H,
Linka T, Klieser E. Effects of newer
atypical antipsychotics on
autonomic neurocardiac function:
A comparison between
amisulpride, olanzapine, sertindoleand clozapine. J ClinPsychopharmacol 2001, 21: 8-13.
Agelink MW, Majewski T,
Wurthmann C, Postert T, Linka T,
Rotterdam S, Klieser E. Autonomic
neurocardiac function in patients
with major depression and effects
of antidepressive treatment with
nefazodone. J Affect Dis 2001, 62:
187-198.
Eich H, Agelink MW, Lemmer W,
Lehmann E, Klieser E. Akupunktur
bei leichten bis mittelschweren
depressiven Episoden und
Angststörungen: Ergebnisse einer
experimentiellen Untersuchung.
Fortschr Neurol Psychiat 2000, 68:
137-144.
Agelink MW, Zeit T, Baumann B,
Majewski T, Lemmer W, Postert T,
Lukas K, Klieser E. In vivo
cardiovascular effects of the new
atypical neuroleptic sertindole. Int J
Psychiatry Clin Pract 2001, 5:
33-40.
Agelink MW, Malessa R,
Baumann B, Majewski T, Akila F,
Zeit T, Ziegler D. Standardized
tests of heart rate variability (HRV):
Normal ranges obtained from 309
healthy humans and effects of age,
gender and heart rate. ClinAutonom Res 2001; 11:99-108.
Agelink MW, Majewski T, Andrich
J, Mück-Weymann M. Short term
effects of intravenous
benzodiazepines on autonomic
neurocardiac regulation in man. A
comparison between midazolam,
diazepam and lorazepam. Crit
Care Med 2002; 30: 997-1006.
Agelink MW, Andrich J, Postert T,
Würzinger U, Zeit T, Klotz P,
Przuntek H. Relationship between
electroconvulsive therapy (ECT),
cognitive side effects,
neuron-specific enolase and
protein S-100. J Neurol Neurosurg
& Psychiatry 2001; 71:394-396.
Agelink MW, Brockmeyer N,
Ullrich H. Sildenafil does not
influence autonomic neurocardiac
control assessed by standard
measurements of heart rate
variability Circulation 2001; 104:
pE145.
Agelink MW, Ullrich H, Baumann
B, Strum S, Majewski T. Effects of
reboxetine, a selective
norepinephrine re-uptake inhibitor,
on sympathetic and
parasympathetic outflow to the
heart. Psychopharmacology 2002;
163: 151-156.
Andrich J, Schmitz T, Saft, C,Bingöl HR, Kraus P, Epplen JT,Przuntek H, Agelink MW.
Autonomic nervous systemfunction in Huntington Disease. JNeurol Neurosurg & Psychiatry2002; 72: 726-731.
Mück-Weymann M, Acker J,
Agelink MW. Autonomic
responses of blood vessels and
sweat glands in patients with
schizophrenia treated with
olanzapine or clozapine.
Psychopharmacology 2001; 157:
368-372.
Agelink MW, Schmitz T, Rembrink
K, Beckerling D, Mück-Weymann
M, Brockmeyer NH.
Cardiovascular effects of sildenafil
citrate (viagraÒ):A naturalistic
cross-over study. Eur J Med Res
2001; 6: 459-464.
Baumann B, Bielau H, Krell D,
Agelink MW, Diekmann S,
Wurthmann C, Trübner K,
Bernstein HG, Danos P, Bogerts B.
(mit Unterstützung der Deutschen
Forschungsgemeinschaft - DFG
799/6-1 - und dem Ministerium für
Bildung und Forschung - BMBF 01
ZZ 9510-). Circumscribed
numerical deficit of dorsal raphe
neurons in mood disorders.
Agelink MW, Boz C, Ullrich H,
Andrich J. Relationship between
major depression and heart rate
variability. Clinical consequences
and implications for antidepressive
treatment. Psychiatry Res 2002;
113: 139-149
Agelink MW. Prolongation of QTc
interval and antipsychotics. Am J
Psychiatry 2002; 159:1063.
Agelink MW, Ullrich H,
Passenberg P, Sayar K,
Brockmeyer NH. Superior safety of
reboxetine over amitryptiline in the
elderly: a case report. Eur J Med
Res 2002; 7: 415-416.
Mück-Weymann M, Moesler T,
Joraschky P, Rebensburg M,
Agelink MW. Depression
modulates autonomic cardiac
control: a physio-psychological
pathway linking depression and
mortality. German J Psychiatry
2002; 5: 67-69.
Agelink MW, Sanner D, Eich H,
Pach J, Bertling R, Lemmer W,
Klieser E, Lehmann E. Beeinflußt
Akupunktur die autonom kardialeRegulation bei Patienten mitleichten depressiven Episodenoder Angststörungen? FortschrNeurol Psychiat; 2003; 71:141-149.
Agelink MW, Sayar K, Klieser E.
Usefulness of heart rate variability
(HRV) for monitoring clozapine
plasma levels.
Pharmacopsychiatry 2003; 36:
166-167.
Kavuk I, Yavuz A, Cetindere Ü,
Agelink MW, Diener HC.
Epidemiology of chronic daily
headache. Eur J Med Res 2003; 8:
236-240
Ullrich H, Passenberg P. Agelink
MW.
Depressive Störung mit
Suizidversuch nach Einnahme von
Valsartan-Hydrochlorothiazid.
Deutsch Med Wochenschr (DMW)
2003; 128: 2534-2536
Loeffler S, Fehsel K, Henning U,
Fischer J, Agelink MW,
Kolb-Bachofen V,
Increased apoptosis of neutrophilsin a case of clozapine-inducedagranulocytosis.
Pharmacopsychiatry 2003; 36:37-41.
Kavuk I, Agelink MW, Gaertner T,
Kastrup O, Doerfler A, Maschke M,
Diener HC. Wernicke`s
encephalopathy: unsual contrast
enhancement revealed by
magnetic resonance imaging. Eur
J Med Res 2003; 8: 492-494
Kämpf P, Agelink MW, Maß R,
Jahn H, Schäfer I, Naber D.
Amisulpride in addition to
clozapine: a retrospective study
indicates improved efficacy and
good tolerability. German J
Psychiatry 2003; 6: 64-68
Agelink MW, Baumann B, Sanner
D, Kavuk I, Mück-Weymann M.
Komorbidität zwischen
kardiovaskulären Erkrankungen
und Depressionen. Deutsch Med
Wochenschr (DMW) 2004; 129:
697-700
Kavuk I, Katsarava Z, Stang A,
Agelink MW, Limmroth V, Diener
HC. Neues zur Epidemiologie von
Kopfschmerzen. Fortschr Neurol
Psychiatr 2004; 72: 184-191
Agelink MW, Klimke A, Cordes J,
Sanner D, Kavuk I, Malessa R,
Klieser E, Baumann B. A
functional-structural model tounderstand cardiac autonomicnervous system (ANS)dysregulation in affective illnessand to elucidate the ANS effects ofantidepressive treatment. Eur JMed Res 2004; 9: 37-50 Agelink MW, Kavuk I, Ak I.
Clozapine combined with
amisulpride for refractory
schizophrenia: a retrospective
analysis of 7 cases. Am J
Psychiatry 2004; 924-925
Agelink MW, Baumann B, Sanner
D, Kavuk I, Mück-Weymann M.
Komorbidität zwischen
kardiovaskulären Erkrankungen
und Depressionen. PsychoNeuro
2004; 30: 541-547
Andrich J, Saft C, Arz A, Schneider
B, Agelink MW, Kraus PH, Kuhn
W, Muller T.
Hyperhomocysteinaemia in treated
patients with Huntington’s disease.
Mov Disord 2004; 19: 226-228
Kavuk I, Koeppen S, Agelink MW,
Doerfler A, Limmroth V, Diener
HC. Transient MRI abnormalities
associated with partial status
epilepticus. J Neurol 2004; 251:
1156-1157
Kavuk I, Yavuz A, Cetindere U,
Agelink MW, Diener HC. Chronic
headache: a focus on medication
overuse. Eur J Med Res 2004; 9:
285
Nach Einreichen der
Habilitationsschrift

Cordes J, Streit M, Loeffler S,
Wilmsdorff M, Agelink MW, Klimke
A. Reversible neutropenia during
treatment with olanzapine: three
case reports. World J Biol
Psychiatry 2004; 5: 230-234
Selekler HM, Kavuk I, Agelink
MW
, Komsuoglu S. Questioning
aggravation of headache during
migraine attacks. Eur J Med Res
2004; 9: 279-281
Kavuk I, Katsarava Z, Selekler M,
Sayar K, Agelink MW, Limmroth
V, Diener HC. Clinical features and
therapy of medication overuse
headache. Eur J Med Res 2004; 9:
565-569
Kämpf P, Agelink MW, Naber D.
Augmentation of clozapine with
amisulpride. Pharmacopsychiatry
2005; 38: 39-40
Cordes J, Mobascher A, Arends M,
Agelink MW, Klimke A. Ein neues
Behandlungsverfahren der
Depression: Die repetitive
transkranielle Magnetstimulation
(rTMS). Deutsch Med Wochenschr
2005; 130: 889-892
Bielau H, Mawrin C, Krell D,
Agelink MW, Truebner K, Davis R,
Gos T, Bogerts B, Bernstein HG,
Baumann B. Differences in
activation of the dorsal raphe
nucleus depending on
performance of suicide. Brain Res
2005; 1039: 43-52
Kavuk I, Hufnagel A, Agelink MW,
Limmroth V, Dörfler A, Sayar K,
Selekler M, Diener HC, Koeppen
S. MRI changes with associated
with partial status epilepticus. Eur J
Med Res 2005; 10: 243-246
Mobascher J, Zielasek J, Schuier
FJ, Mobascher A, Grohmann R,
Agelink MW, Cordes J.
Guillan-Barre-syndrome after
septicemia following
clozapine-induced agranulocytosis.
Pharmacopsychiatry 2005; 38:
329-330
Bielau H, Truebner K, Krell D,
Agelink MW, Bernstein HG,
Stauch R, Mawrin C, Danos P,Gerhard L, Bogerts B, Baumann B.
Volume deficits of subcorticalnuclei in mood disorders: a postmortem study. Eur Arch PsychiatryClin Neurosci 2005; 255: 401-412.
Siepmann M, Joraschky P,
Rebensburg M, Rittger H, Mösler
T, Agelink MW, Mück-Weymann
M. Ist die autonome kardiale
Regulation bei Patienten mit
Depression und koronarer
Herzerkrankung gestört? Zeitschr
Klin Psychol Psychother
2005;34:277-281
Blaschke S, Kornischka J, Agelink
MW.
Deutliche Gewichtsreduktion
nach Aripiprazol. Nervenheilkunde
2005; 24: 426-427
Fehsel K, Loeffler S, Krieger K,
Henning U, Agelink MW,
Kolb-Bachofen V, Klimke A.
Clozapine induces oxidative stress
and proapoptotic gene expression
in neutrophils of schizophrenic
patients. J Clin Psychopharmacol
2005; 25: 419-426
Cordes J, Klimke A, Kornischka J,
Agelink MW, Hauner H. Therapie
der Schizophrenie mit
Antipsychotika: Gewichtszunahme
ist ein relevanter Faktor. Der
Neurologe & Psychiater (DNP)2006: 1-2: 45-51.
Cordes J, Arends M, Mobascher A,
Brinkmeyer J, Kornischka J,
Eichhammer P, Klimke A, Winterer
G, Agelink MW. Potential clinical
targets of repetetive transcranial
magnetic stimulation treatment in
schizophrenia.
Neuropsychobiology 2006; 54:
87-99
Agelink MW, Kornischka J,
Cordes J, Klimke A, Hauner H,
Ziegler D. Allgemeinmedizinische
Aspekte der Therapie mit
Antipsychotika der zweiten
Generation. Deutsches Ärzteblatt
2006; 2437-2443
Kornischka J, Cordes J, Agelink
MW
. 40 Jahre Beta-Blocker in der
Psychiatrie: Eine systematische
Übersicht. Fortschr Neurol
Psychiatr 2007; 75: 199-210
Kornischka J, Assion HJ, Machleidt
K, Agelink MW. Psychische und
psychosoziale Probleme bei
Spätaussiedlern. Psychiatr Prax
2008; 35: 60-66.
Baer J, Wernich K, Boettger S,
Cordes J, Boettger MK, Loeffler S,
Kornischka J, Agelink MW.
Relationship between cardiovagal
modulation and psychotic state in
patients with schizophrenia.
Psychiatry Res 2008; 157:
255-257.
Luckhaus, C, Hennersdorf M, Bell
M, Agelink MW, Zielasek J,
Cordes J. Brugada-syndrom as a
potential cardiac risk factor during
electroconvulsive therapy. World J
Biol Psychiatry 2008; 9: 150-153
Stirban A, Laude D, Elghozi JL,
Sander D, Agelink MW, Hilz MJ,
Ziegler D. Acute effects of
sildanefil on flow mediated
dilatation and cardiovascular
autonomic nerve function in type-2
diabetic patients. Diabetes Metab
Res Rev 2009; 25: 136-143.
Siepmann M, Rauh R, Dill O,
Agelink MW, Mück-Weymann M.
The effects of sildenafil on heart
rate variability in healthy subjects.
J Cardiovasc Pharmacol 2007; 50:
598-600.
Baer KJ, Boettger MK,Andrich J,
Epplen JT,Fischer F, Cordes J,
Koschke M, Agelink MW.
Cardiovagal modulation upon
postural change is altered in
Huntington´s disease. J Neurol
Neurosurg and Psychiatry 2008;
15: 869-871
Baer KJ, Boettger MK, Schulz S,
Harzendorf C, Agelink MW,
Yeragani VK, Chokka P, Voss A.
The interaction between pupil
function and cardiovascular
regulation in patients with acute
schizophrenia. Clin Neurophysiol
2008; 119: 2209-2213.
Boettger MK, Baer KJ, Dohrmann
A, Müller H, Mertins L, Brockmeyer
NH, Agelink MW.Increased vagal
modulation in atopic dermatitis. J
Dermatol Sci 2009; 53: 55-59.
Cordes J, Sinha-Röder A, Kahl
KG, Malevani J, Thuenker J,
Lange-Asschenfeldt C, Hauner H,
Agelink MW, Klimke A.
Therapeutische Optionen für ein
Gewichts-managementprogramm
bei mit atypischen Antipsychotika
behandelten schizophrenen
Patienten. Fortschr Neurol
Psychiatr 2008; 76: 703-714.
Mobascher A, Arends M,Eschweiler GW, Brinkmeyer J, Agelink MW, Kornischka J,
Winterer G, Cordes J. Biological
correlates of prefrontal activating
and temperoparietal inhibiting
treatment with repetitive
transcranial magnetic stimulation
(rTMS). Fortschr Neurol Psychiatr
2009; 77; 432-443.
Mittrach M, Thünker J, Winterer G,
Agelink MW, Regenbrecht G,
Arends M, Mobascher A, Kim SJ,
Wölwer W, Brinkmeyer J, Gaebel
W, Cordes J. The tolerability of
rTMS treatment in schizophrenia
with respect to cognitive function.
Phramacopsychiatry 2010; 43:
110-117.
Baer KJ, Ebert A, Boettger MK,
Merz S, Kiehntopf M, Jochum T,
Juckel G, Agelink MW. Is
successful electroconvulsive
therapy (ECT) related to
stimulation of the vagal system? J
Affect Disord 2010; 125: 323-329.
Cordes J, Thünker J, Agelink MW,
Arends M, Mobascher A, Wobrock
T, Schneider-Axmann T,
Brinkmeyer J, Mittrach M,
Regenbrecht G, Wölwer „W,
Winterer G, Gaebel W. Effects of
10Hz repetitive transcranial
magnetic stimulation (rTMS) on
clinical global impression in chronic
schizophrenia. Psychiatr Res
2010; 177: 32-36.

Source: http://herford.work.conquest-cms.net/de/Kliniken/Psychiatrie/Fachkreise/Publikationsverzeichnisse/peerreview/content.pdf

May 2004.pub

A d v a n ci n g W h y a l l a I n v i t es Where: Westlands Hotel (Oasis Function L i gh t R ef r esh m en t s P r ov i d ed / B a r op en IN SID E TH IS ISSU E: Email: advwhy@centralonline.com.au The evening will feature a presentation from Yolie Entsch who will also facili-tate a brainstorming activity and feedback forum. Yolie is a highly respected motivational speaker with

Microsoft word - s-3007_1_engl.doc

BöttcherFount S-3007 Fountain Solution Additive for IPA-free printing BöttcherFount S-3007 is a fountain solution additive for sheet-fed printing and for continuous form printing, particularly for alcohol-free printing. For IPA-free printing or IPA reduction 0 - 5% pH-value 4,9 - 5,5 (depends on hardness of water) suitable for water hard

Copyright © 2010-2014 Pdf Medical Search